Navigation Links
Gene Test Could Boost Myeloma Treatment
Date:9/20/2007

Certain DNA influences who'll respond best to therapy, scientists say

THURSDAY, Sept. 20 (HealthDay News) -- Analyzing the activity of a small subset of genes may help identify patients with the worst cases of multiple myeloma, U.S. researchers say.

It may also help guide their treatment, noted the team from the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences.

Multiple myeloma is a cancer that affects the blood plasma cells in bone marrow that produce antibodies. There is wide variation in how well multiple myeloma patients respond to treatment.

This study included 532 patients who were followed for seven years after they had a blood stem cell transplant. The researchers created a genetic profile of each patient to chart the severity of their multiple myeloma.

They found that the activity of as few as 17 genes could determine whether a patient was at high or low risk for a poor prognosis.

The findings were to be presented this week at an American Association for Cancer Research conference in Atlanta.

"There are enormous differences between how different people fare with multiple myeloma. While most do very well, others have a highly aggressive form of the disease, and this is not recognized well with current prognostic variables," lead researcher John D. Shaughnessy Jr., a professor of medicine at the Myeloma Institute for Research and Therapy, said in a prepared statement.

"If we can categorize a patient's risk early, we can better guide that patient toward therapies that might be more effective for them based on the genetic profile of the disease," he explained.

More information

The American Cancer Society has more about multiple myeloma.



-- Robert Preidt



SOURCE: American Association for Cancer Research, news release, Sept. 18, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Virus Level could Predict Cervical Cancer Risk
2. Lean Protein Could Be Key to Obesity Drugs
3. Nasal Spray Could Take Drugs Direct to Brain.
4. Beware of the oral patch! It could be cancer!!!
5. Low Birth Weight infants could have Problems in the Future
6. False beliefs could cost cancer patients their lives
7. Oxygen Usage During Exercise Could Indicate Heart Problems
8. Prozac miracle could end in disaster
9. Wonder drug - could end in disaster
10. Pollution could be a risk
11. Fright could be more harmful
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: